APRIL flowers for Otsuka in IgAN; Vertex’s plus-BAFF last laugh? J.P. Morgan analyst Jessica Fye said officials at Vertex Pharmaceuticals Inc. were “unfazed” by Otsuka Pharmaceutical Co. Ltd.’s new data from the phase III, 605-patient Visionary trial showing that Voyxact (sibeprenlimab), the groundbreaking A proliferation inducing ligand (APRIL) blocker cleared by the U.S. FDA last year for proteinuria in IgA nephropathy (IgAN), stabilizes estimated glomerular filtration rate and returns declined kidney function to the baseline physiologic rate over a two-year period.